c Macrolide-resistant Mycoplasma pneumoniae is an increasing problem worldwide but is not well documented in the United States. We report a cluster of macrolide-resistant M. pneumoniae cases among a mother and two daughters.
and headache on 27 December 2012, approximately 2 weeks after the onset of fever in patient 2 and 5 weeks after the onset in patient 1. She had a temperature of 98.8°F in the office on day 2, and rhonchi were heard in the left anterior chest upon auscultation. Because of persistent headache, dizziness, and cough, she was reevaluated in the PCP's office on day 5. Auscultation revealed inspiratory rales in the left anterior chest, and chest radiography showed lingular pneumonia. Her PCP prescribed a 7-day oral course of cefdinir due to the recent history of pneumonia in the family that did not respond to azithromycin. Blood specimens were obtained for complete blood count (CBC), culture, and erythrocyte sedimentation rate (ESR) analyses, and two NP specimens were collected for viral and Mycoplasma pneumoniae PCR. The laboratory results came back on day 9 and were as follows: CBC was normal; ESR was elevated (23 mm/h [normal range, 0 to 20]); blood culture was negative; a respiratory viral PCR panel (Quest Diagnostics) was negative; and M. pneumoniae DNA qualitative real-time PCR (Quest Diagnostics) was positive. Because of the positive PCR result for M. pneumoniae, she was started on doxycycline treatment. She improved with no further fever, but doxycycline was discontinued on day 11 because of vomiting. The total illness course was 11 days.
NP specimens (n ϭ 2) collected from patient 3 were transferred from the Quest Diagnostics laboratory to the Centers for Disease Control and Prevention (Atlanta, GA) for confirmatory testing for M. pneumoniae by qPCR and culture and for determination of macrolide susceptibility. Isolation was performed using SP4 medium (Remel) as previously described (1). Total nucleic acid was extracted from NP specimens and liquid culture medium using a MagNA Pure Compact instrument with total nucleic acid isolation kit I (Roche Applied Science, Indianapolis, IN) according to the manufacturer's instructions. M. pneumoniae-specific quantitative PCR (qPCR) was performed as previously described (2) . Both NP specimens were positive for M. pneumoniae; the threshold cycle (C T ) values were approximately 15 for both speci-men extracts (data not shown), indicating a relatively large amount of M. pneumoniae nucleic acid present in each specimen. An isolate was obtained from each specimen.
Both NP specimens and the corresponding isolates were tested for macrolide resistance using a qPCR assay with Light Upon Extension (LUX) chemistry and high-resolution melt (HRM) analysis to identify single-base mutations in the 23S rRNA gene that confer resistance to macrolide antibiotics (3). Melt patterns consistent with macrolide resistance were observed for both specimens and isolates (Fig. 1) . DNA sequencing of the amplicon was performed as previously described (3); sequencing analysis revealed the presence of the A2063G mutation in the 23S rRNA gene, a single-base mutation previously shown to confer macrolide resistance in M. pneumoniae (3) ( Table 1) .
Primary specimens and isolates were characterized by multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) using previously described methods (4, 5) . Both primary specimens and isolates displayed virtually identical MLVA types (5/4/5/7/2), although variation at the Mpn1 locus was identified in one of the primary specimens and the corresponding isolate, a phenomenon that has been reported previously (4) . This specimen and isolate displayed two distinct fragment sizes corresponding to two and five repeats at this VNTR locus ( Table 2 ). Molecular typing of the gene encoding the P1 major adhesion protein using qPCR with high-resolution melt analysis identified both isolates as type 1 (Table 2) (6).
M. pneumoniae is a major cause of community-acquired pneumonia among children and adults. Since 2000, reports of the incidence of macrolide-resistant M. pneumoniae isolates have increased worldwide, perhaps due in part to the expanded use of improved diagnostic methods (7). Macrolide-resistant M. pneumoniae has been implicated in individual cases, family clusters, and outbreaks in various settings in the United States and other countries (8) (9) (10) (11) (12) . The prevalence of resistance among isolates from case series and surveillance studies in the literature ranges from 8% to 27% (13) (14) (15) . We describe a household cluster of presumed macrolide-resistant M. pneumoniae infections diagnosed 45 days after the onset of symptoms in the index case, including laboratory confirmation in the third case. This household (21) ; this longer fever duration is similar to the fever profile of patients described in this cluster. The clinical courses of the three patients were similar; all patients had radiological evidence of pneumonia, multiple medical consultations, and multiple courses of antimicrobials. Two of the patients described in this cluster received macrolide treatment with no clinical improvement. The last patient (for whom the diagnosis was laboratory confirmed) did not receive macrolide treatment but was given cefdinir, to which she did not respond. Clinical improvement was noted after the administration of doxycycline. The prolonged duration of symptoms and nonresponse to macrolide therapy suggest that the level of macrolide resistance conferred by the genetic mutation detected here was clinically significant and resulted in treatment failure in these otherwise healthy patients.
Macrolide resistance in M. pneumoniae is caused by specific point mutations within the single-copy 23S rRNA gene which inhibit the interaction of macrolides with the large ribosomal subunit, thereby allowing protein synthesis to proceed (22) . Sequencing analysis of specimens obtained from patient 3 demonstrated the presence of the A2063G transition in the 23S rRNA gene, a mutation commonly associated with macrolide resistance in M. pneumoniae (23, 24) . The high burden of M. pneumoniae in patient 3, as indicated by the low C T values in the detection assay, allowed the clear identification of macrolide resistance directly from the primary specimen extract without the need for an isolate.
Assays for the characterization and typing of M. pneumoniae, including P1 typing and MLVA, were utilized in this investigation. These assays can help to elucidate the relatedness of strains in outbreaks or clusters such as the one reported here. Unfortunately, specimens were available from only one of the three related cases in this report, precluding any comparison of M. pneumoniae data among family members. However, the close family contact, similarity of symptoms, and time courses of the three cases, with onset of the second and third cases occurring within the known incubation period of M. pneumoniae after onset of the first case, suggest that all three illnesses were caused by the same strain.
Macrolides such as erythromycin, clarithromycin, and azithromycin are used as first-choice therapeutic agents for treating M. pneumoniae infections. This is especially important for children, as other classes of antibiotics with activity against M. pneumoniae are not indicated or may cause adverse events in young patients (25) . The advantages of clarithromycin and azithromycin over erythromycin include improved oral bioavailability, longer halflife (allowing once-or twice-daily administration), higher tissue concentrations, enhanced antimicrobial activity, and reduced gastrointestinal adverse effects (25) . Recent studies have demonstrated that tetracyclines and fluoroquinolones are effective treatments for patients with macrolide-resistant M. pneumoniae infections (26) . In particular, administration of minocycline was shown to decrease the number of DNA copies found in the nasopharynxes of children with macrolide-resistant M. pneumoniae infections (27) .
This familial cluster of macrolide-resistant M. pneumoniae infections highlights the need for increased awareness among clinicians of circulating macrolide-resistant M. pneumoniae strains. Clinicians considering M. pneumoniae as part of a differential diagnosis should consider macrolide resistance if there is no clinical improvement after the initiation of first-choice antibiotics. Earlier detection of M. pneumoniae and its resistance profile would likely reduce the inappropriate or unnecessary use of antibiotics, the duration and severity of illness, and the spread of infection in the community. Early detection and proper treatment of macrolideresistant M. pneumoniae pneumonia could also be important for prevention of outbreaks in congregate settings. Reliable diagnostic tests for rapid identification of both macrolide-sensitive and macrolide-resistant M. pneumoniae strains as well as public health programs to monitor disease are needed to understand the true burden of infections due to this pathogen and to monitor trends in antibiotic resistance.
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